AP Skin 01
Latest Information Update: 04 Feb 2021
At a glance
- Originator APstem Therapeutics
- Class Antihyperglycaemics; Cell therapies; Foot disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic foot ulcer
- Research Diabetes mellitus
Most Recent Events
- 29 Oct 2020 Early research in Diabetes mellitus in USA (Parenteral) (APstem Therapeutics Pipeline, October 2020)
- 29 Oct 2020 Preclinical trials in Diabetic foot ulcer in USA (Parenteral)
- 29 Oct 2020 APstem Therapeutics completes of an INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meeting with the US FDA Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies